Literature DB >> 11238533

Urocortin and corticotropin-releasing factor receptor expression in normal cycling human ovaries.

Y Muramatsu1, N Sugino, T Suzuki, K Totsune, K Takahashi, A Tashiro, M Hongo, Y Oki, H Sasano.   

Abstract

Urocortin is a member of the CRF neuropeptide family and has a 43% homology to CRF in amino acid sequence. Urocortin has been found to bind with high affinity to CRF receptors. CRF has been detected in the human ovary and has been demonstrated to suppress ovarian steroidogenesis in vitro. In this study we examined urocortin and CRF receptor expression in normal cycling human ovaries, using immunohistochemistry and RT-PCR. Normal cycling human ovaries were obtained at oophorectomy and hysterectomy from patients who underwent surgery for cervical cancer or myoma uteri. Intense urocortin immunoreactivity was detected in luteinized thecal cells of regressing corpora lutea, in which only luteinized thecal cells have the capacity for steroidogenesis. Immunoreactive urocortin was also detected in luteinized granulosa and thecal cells of functioning corpora lutea, in which both cell components are capable of producing steroids. RT-PCR analyses revealed that messenger ribonucleic acid levels for urocortin, CRF, and CRF receptor type 1 and type 2alpha were significantly higher in the regressing corpus luteum than in the functioning corpus luteum. The spatial and temporal immunolocalization patterns of CRF receptor were similar to those of urocortin. These results suggest that urocortin is locally synthesized in steroidogenic luteal cells and acts on them as an autocrine and/or paracrine regulator of ovarian steroidogenesis, especially during luteal regression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238533     DOI: 10.1210/jcem.86.3.7299

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

Review 2.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

Review 3.  Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery?

Authors:  Huayuan Zhu; Juejin Wang; Jianyong Li; Shengnan Li
Journal:  Inflamm Res       Date:  2011-04-08       Impact factor: 4.575

4.  An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population.

Authors:  Xing Gu; Peng Qi; Feiguo Zhou; Qiang Ji; Hao Wang; Tonghai Dou; Yunpeng Zhao; Chunfang Gao
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

5.  Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system.

Authors:  Kazuhiro Takahashi
Journal:  Int J Endocrinol       Date:  2012-05-17       Impact factor: 3.257

6.  Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.

Authors:  V Minas; A Rolaki; S N Kalantaridou; J Sidiropoulos; S Mitrou; G Petsas; U Jeschke; E A Paraskevaidis; G Fountzilas; G P Chrousos; N Pavlidis; A Makrigiannakis
Journal:  Br J Cancer       Date:  2007-07-31       Impact factor: 7.640

Review 7.  Corticotropin-Releasing Factor Family: A Stress Hormone-Receptor System's Emerging Role in Mediating Sex-Specific Signaling.

Authors:  Lahari Vuppaladhadiam; Cameron Ehsan; Meghana Akkati; Aditi Bhargava
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

Review 8.  Urocortins in the mammalian endocrine system.

Authors:  Caterina Squillacioti; Alessandra Pelagalli; Giovanna Liguori; Nicola Mirabella
Journal:  Acta Vet Scand       Date:  2019-10-04       Impact factor: 1.695

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.